The Subcutaneous Biologic Drugs and Affiliated Technologies Market is Estimated to be Worth Over USD 180 Billion by 2030, Claims Roots Analysis
LONDON, May 26, 2020 /PRNewswire/ -- Roots Analysis has announced the addition of "Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030" report to its list of offerings.
Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this link
Key Market Insights
More than 180 organizations claim to be engaged in the development of subcutaneous biologics
The market is characterized by the presence of over 100 approved biologics, while more than
350 such drug candidates are presently being evaluated across different clinical stages. Of the total number of such drugs, over 115 are intended for treating autoimmune disorders, followed by
metabolic disorders (65+) and oncological disorders (60+).
300+ subcutaneous drug delivery systems are presently available / under development
More than 100 of these subcutaneous drug delivery systems are large volume wearable injectors and
autoinjectors. In addition, we identified around 80 pen-injectors and close to 40 needle free injectors that are designed to facilitate subcutaneous drug delivery.
Over 90% of subcutaneous formulation technology developers are small or mid-sized players Further, more than 60% of such companies are based in North America; key hubs in the region include (in decreasing order of number of companies) Massachusetts, California and New Jersey. It is also worth noting that most of the available technology platforms (over 70%) are either focused on facilitating the delivery of highly concentrated / viscous protein formulations, or enabling extended / controlled / sustained delivery of biologics.
Several partnerships have been inked by subcutaneous formulation technology developers since 2011
The report covers over 50 deals, most of which (18) were signed in 2018 and 2019. It
is worth highlighting that around 40% of the total partnerships were technology licensing agreements, followed by deals related to formulation development (30%).